Trial Profile
Reinduction with liposomal anthracyclines and Capecitabine in patients with breast cancer, locally advanced (IIIA-IIIB-IIIC) HER2 negative, not obtaining a pathological complete response (<PCR) after primary chemotherapy.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2012
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Doxorubicin liposomal (Primary)
- Indications HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms ICARO 2
- 22 Mar 2012 New trial record